To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013
16-05-2013
In the first six months of financial year 2012/2013 medical technology company Carl Zeiss Meditec increased its revenue by 2.6% compared with the same period of the previous year, to € 443 million. Earnings before interest and tax improved to € 64.1 million (previous year: € 61.1 million); ...
Evonik selects OPX Biotechnologies for joint development of bio-based chemicals
16-05-2013
OPX Biotechnologies, Inc. (OPXBIO) and Evonik Industries AG announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for OPXBIO to use its proprietary EDGE™ (Efficiency ...
Frost & Sullivan commends Merck Serono for its excellence in product differentiation
16-05-2013
Merck Serono announced that based on its recent analysis of the human growth hormones (HGH) market, Frost & Sullivan recognises Merck Serono with the 2013 Europe Product Differentiation Excellence Award. “Merck Serono is lauded for its cutting-edge drug delivery devices - easypod® and ...
SYGNIS reports results for the first quarter of 2013
16-05-2013
SYGNIS Pharma AG announced its financial results according to IFRS for the first quarter of 2013, ending 31 March 2013. In the first quarter of 2013, revenues amounted to €0.1 million; operating expenses amounted to €1.3 million. Operating expenses include sales, general & administrative ...
ZEISS presents half-year financial figures
15-05-2013
During the first six months of fiscal year 2012/13 the business trend in the ZEISS Group was marked by the difficult conditions experienced in some markets. Nevertheless, the Group concluded the first half of the year (ended 31 March) with revenue totaling EUR 1.978 billion (first six months ...
Evogene reports first quarter 2013 financial results
14-05-2013
Evogene Ltd. (EVGN) announced its financial results for the first quarter ended March 31, 2013. Revenues for the first quarter of 2013 grew to $4.6 million, compared to $4.2 million for the same period in 2012. Evogene’s current revenues consist primarily of research and licensing revenues ...
Analytik Jena to develop products for sepsis diagnostics
All assets taken over from insolvent company SIRS-Lab GmbH
08-05-2013
Analytik Jena has acquired all of the assets of the insolvent company SIRS-Lab GmbH as part of an asset deal. SIRS-Lab, a company that develops molecular diagnostics methods and testing systems for life-threatening infections like sepsis, had filed for insolvency in December 2012. Analytik ...
Analytik Jena AG establishes subsidiary in Thailand
07-05-2013
Analytik Jena AG has established a new subsidiary, Analytik Jena Far East (Thailand) Ltd., giving it a presence in the Southeast Asian market. Analytik Jena AG is using this new company to bolster its activities in the Southeast Asian market, increase its regional service for the sales ...
CLC bio moves Danish headquarters to landmark building in Aarhus
06-05-2013
On May 1st, CLC bio moved their Danish headquarters to Prismet - a local landmark highrise office building in Aarhus. Experiencing significant growth due to a long term positive development in sales, the number of employees at CLC bio has increased by more than 50% worldwide in the past two ...
Unethical advertising at launch of antidepressants
06-05-2013
The new feature of the antidepressant drugs of the 1990s was that they had milder side-effects than their predecessors. Combined with aggressive marketing, this meant that annual sales in Sweden increased from just under EUR 18 million to over EUR 100 million in the space of just a few ...
Netmeeting
